Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

December 31, 2007

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

paclitaxel

Given IV

BIOLOGICAL

trastuzumab

Given IV

DRUG

erlotinib hydrochloride

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00042809 - Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter